It is worth acknowledging the turning out of Oncotarget as among the best scientific journals which are exemplary. The explanation to this is behind its potential alongside the implementation of the many developments handling the subjects that address cancer-fighting. The journal has a number of characteristics. They include its feature of being scientific and that it bases its publication on the subject matter of Oncology. Just like many other subjects, another characteristic of oncology is that it is broad and consists of many sections. The implies that it has been able to consistently commit itself towards the publication process of all the important developments together with the discoveries which the scientists come up with to act as a support to the war against cancer.
The various subjects addressed within Oncology consists of the molecules & the cellular functions in the cancerous cells, cells, atherosclerosis, neuro-degradation, the microbes, the pathways, and lymphocytes.It is noteworthy that before the publication step of any findings submitted, they are passed through a thorough procedure of vetting. The procedure ensures that their review is done and the ascertainment of their truthfulness is done. The implication of a rigorous vetting procedure might even entail carrying out a cross check through the experiments. The execution of this might involve visiting the scientist concerned before the publishing step is reached.
It is after publication that the journal is available for reading by other researchers and the general public. After this step, it then acts as an information-spreading means which is one of the measures of informing people on how to fight the cancer menace. The reason is that the availability of knowledge is the best tool that everyone should possess. Notably, the journal is often termed as an outstanding piece of the scientific know-how due to its several distinct features inclusive of the potential that it has alongside passing through the thorough reviews after submissions. Such is often done through ways that are very quick. The conclusion out of this is therefore that the content of publications made has the potential of spreading without consuming unnecessarily long.
Mikhail Blagosklonny, MD, Ph.D. is one of the renowned scientists behind the research scenes in the fight against cancer and the aging process. His research interest areas included “molecular and cellular biology to clinical investigations and specifically include oncogenes and tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies such as exploiting cancer cell cycling and drug resistance for selective protection of normal cells.” Dr. Blagosklonny is a Professor of Oncology at the Rosewell Park Cancer Institute in Buffalo, NY since 2009. He also served as an Associate Professor of medicine at New York Medical College in Valhalla, NY in 2002 and a Senior Scientist at Ordway Research Institute, Albany, NY. He received both his MD in internal medicine and Ph.D. in experimental medicine from the reputable First Pavlov State Medical University of St. Peterburg in Russia. Read more on Hardware Gurus.
In his role at Rosewell Park Institute, Dr. Blagosklonny is revered for his distinctive concepts he created in cancer therapy and biology. The Impact Journals acknowledged him for his tremendous assistance in facilitating the development of preventive new anti-cancer methods and strategies. As a result of protecting normal body cells from the ill effects of therapeutic treatments, it slows down cancer via the delay in the aging process in organisms. He has also been a proponent fighting cancer through the slowdown of aging and advocated for the use of rapamycin, a standard cancer drug for the possible treatment for a longer life span.
Mikhail Blgosklonny is an Associate Editor of Cancer Biology and Therapy health journal, and doubles as the Founder Editor and Editor in Chief of Cell Cycle, Aging, Oncotarget and Oncoscience Journals. He serves as Editor for Cancer Biology & Therapy, Autophagy, Cancer Research, Cell Death and Differentiation, International Journal of Cancer, The American Journal of Pathology and PLOS ONE respectively. He has published over 300 research articles as well as cancer research reviews and book chapters to his credit. He is the author of “hyperfunction hypothesis of aging including anti-cancer approaches such as cryotherapy and chemotherapeutic engineering.” Read more on templeofthecave.com
An Overview of Oncologist Mikhail Blagosklonny’s Life and Career